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RESEARCH ARTICLE
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Marfan syndrome (MFS) is diagnosed according to the Ghent
nosology, which has recently been revised. In the Netherlands,
evaluation for possible MFS is performed in specialized Marfan
outpatient clinics. We investigated the diagnostic yield in our
clinic and the impact of the 2010 nosology. All adult patients
(n¼ 343) who visited our clinic between 1998 and 2008 were
included.We analyzed their reasons for referral, characteristics,
and established diagnoses. In addition, we applied the 2010
nosology to all patients and compared the outcomes to those
obtained with the 1996 nosology. Diagnoses that were made
using the 1996 and the 2010 Ghent nosology included MFS
(44/343 vs. 47/343), familial thoracic aortic aneurysm and/or
dissection (22/343 vs. 22/343 patients), Loeys–Dietz syndrome
(4/343 vs. 4/343 patients), and (familial) mitral valve prolapse
(MVPS; 5/343 vs. 28/343 patients). In both nosologies, 77% of
MFSpatients had anFBN1mutation. The2010nosology led to an
increase in the number of diagnoses made: 4 additional cases of
MFS were identiﬁed (one patient was ‘‘lost’’ who no longer
fulﬁlled the criteria) and 23 additional cases of MVPS were
diagnosed. The diagnostic yield of patients with aortic root
dilatation was 65% using the 1996 nosology and 70% using
the 2010 nosology. The change in diagnoses did not lead to a
difference in clinical follow-up.We conclude that the diagnostic
yield of our specialized clinic was high, in particular in patients
with aortic root dilatation. Further more the 2010 Ghent nosol-
ogy led to a signiﬁcant increase in thenumber of diagnosesmade,
mainly due to lowering of the diagnostic threshold for MVPS.
 2012 Wiley Periodicals, Inc.
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INTRODUCTION
Marfan syndrome (MFS) is an autosomal, dominantly inherited,
connective tissue disorder with an estimated prevalence of approx-
imately 1–3 in 5,000 [Gray et al., 1994] and it is usually caused by a
mutation in the ﬁbrillin-1 gene (FBN1) [Dietz et al., 1991]. Man-
ifestations of MFS occur in the ocular system, skeletal system,
pulmonary system, skin and integument, central nervous system
(CNS; dural ectasia) and in the cardiovascular system. Character-
istic features of MFS include ectopia lentis (subluxation and
luxation of the lens), thin body habitus and long extremities, pectus
deformities and aortic root dilatation. Evaluation of possible MFS
patients is usually performed in specialized Marfan outpatient
clinics (MOC) and the diagnosis is established according to the
Ghent nosology [De Paepe et al., 1996], which has recently been
revised [Loeys et al., 2010]. The main purpose of evaluation is to
conﬁrm or exclude MFS in a patient, but it may also lead to many
other, clinically relevant diagnoses, such as Loeys–Dietz syndrome
(LDS), familial thoracic aortic aneurysm and/or dissection
(FTAAD), familial mitral valve prolapse syndrome (MVPS), mitral
valve, aorta, skeleton and skin (MASS) phenotype and Ehlers–
Danlos syndrome (EDS). Establishing the correct diagnosis is
important as it provides prognostic information, has implications
for treatment, and also guides (genetic) counseling of family
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members. So far, only two studies [Hamod et al., 2003; Rybczynski
et al., 2008] have reported on the outcome (diagnosis) in
adult patients analyzed for possible MFS. In order to establish
the diagnostic yield of our clinic, we determined the ﬁnal
diagnosis of all the patients referred for evaluation of MFS
in a 10-year period. We were particularly interested in the diag-
nostic yield in patients with cardiovascular manifestations, since
these carry important prognostic implications. Finally, we used
the opportunity to analyze what the diagnostic yield would have
been using the 2010 Ghent criteria [De Paepe et al., 1996; Loeys
et al., 2010].
PATIENTS AND METHODS
Study Population and Diagnostic Evaluations
All adult patients (age 18 years) referred for evaluation for
possible MFS to our clinic between 1998 and 2008 were included
in our study. Every physician who suspected MFS in a certain
patient was allowed to refer this patient to ourMOC and there were
no speciﬁc criteria patients had to meet to allow evaluation. The
reason(s) for referral for all patients was routinely recorded.
Evaluation of the patients was performed by a team of dedicated
specialists, consisting of a clinical geneticist (JPvT), a cardiologist
(MPvdB), an ophthalmologist (BAEvdP), and an orthopaedic
surgeon. Inherent to this period of referral (i.e., up to 2008), the
patient characteristics were collected according to the 1996 Ghent
nosology [De Paepe et al., 1996]. Not all the Ghent criteria
(especially no studies to detect the major criterion dural ectasia
or minor criterion protrusion acetabuli) were evaluated in each
patient, only when clinically relevant, that is, when necessary to
conﬁrm or exclude MFS. All patient data, including echocardio-
graphic data,were routinely fed into a clinical database.Mitral valve
prolapse was deﬁned as echocardiographic single or bileaﬂet pro-
lapse of at least 2mm beyond the long-axis annular plane, with or
without leaﬂet thickening [Hayek et al., 2005]. Finally, it is impor-
tant to note that patients with a bicuspid aortic valve were not
evaluated at this speciﬁc clinic.
Deﬁnitions of MFS and Other Relevant Diagnoses
The diagnoses were established using the 1996 Ghent nosology but,
as part of this study, we also retrospectively applied the 2010 Ghent
nosology to all patients based on their characteristics as collected
at the time of referral. Other diagnoses that could be made but are
not mentioned in (one) of the Ghent nosologies were also
established.
The 1996 nosology for MFS distinguished major and minor
criteria in different (organ) systems. MFS was present if two major
(organ) systems were involved and if a third (organ) system was
involved in a minor way [De Paepe et al., 1996]. To deﬁne aortic
root dilatation,weused aZ-score2, in the 1996nosology aswell as
in the 2010 nosology. In the 2010 nosology, there is no differ-
entiation between major and minor criteria. Aortic root dilatation
(Z-score 2) combined with one of the following characteristics
establishes a diagnosis of MFS (see also Table I): ectopia lentis,
FBN1 mutation, family history of MFS, or a systemic score 7. A
family history of MFS combined with ectopia lentis or a systemic
score 7 also establishes a diagnosis of MFS [Loeys et al., 2010].
Besides deﬁning MFS, the 2010 Ghent nosology also considers
disorders that need to be differentiated from MFS. These include
TABLE I. Diagnostic Criteria for MFS in Adults According to the 2010 Ghent Nosology
In the absence of a family history of MFS:
1. Aortic root Z-score 2 AND ectopia lentis
2. Aortic root Z-score 2 AND an FBN1 mutation
3. Aortic root Z-score 2 AND a systemic score* 7 points
4. Ectopia lentis AND an FBN1 mutation with known aortic pathology
In the presence of a family history of MFS (as deﬁned above):
1. Ectopia lentis
2. Systemic score* 7
3. Aortic root Z-score 2
*Points for systemic score
Wrist AND thumb sign¼ 3 (wrist OR thumb sign¼ 1)
Pectus carinatum deformity¼ 2 (pectus excavatum or chest asymmetry¼ 1)
Hindfoot deformity¼ 2 (plain pes planus¼ 1)
Dural ectasia¼ 2
Protrusio acetabula¼ 2
Reduced upper segment/lower segment ratio AND increased arm/height AND no severe scoliosis¼ 1
Scoliosis or thoracolumbar kyphosis¼ 1
Reduced elbow extension¼ 1
Facial features (3/5)¼ 1 (dolichocephaply, enophthalmos, downslanting palpebral ﬁssures, malar hypoplasia, retrognathia)
Skin striae¼ 1
Myopia >3 diopters¼ 1
Mitral valve prolapse¼ 1
MFS, Marfan syndrome.
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MASS phenotype, MVPS (familial or incidental) [Hayek et al.,
2005], FTAAD,EDS[Beightonet al., 1998], LDS [Loeys et al., 2006],
and ectopia lentis syndrome [De Paepe et al., 1996; Loeys et al.,
2010]. Deﬁnitions of these disorders have not been provided
in the 1996 Ghent nosology but were added to the 2010 Ghent
nosology, such as FTAAD, LDS and ectopia lentis syndrome.
In the 1996 Ghent nosology, however, the MASS phenotype
and MVPS are mentioned although not clearly deﬁned.
The 1996 nosology mentions the MASS phenotype as the
presence of three of the following manifestations: myopia,
mitral valve prolapse, borderline aortic root dilatation, striae,
and minor skeletal criteria. In the 2010 nosology, a MASS pheno-
type is deﬁned as borderline aortic root dilatation and a systemic
score >5 with at least one skeletal feature deleting the skin
and eye manifestations. MVPS is mentioned in the 1996
nosology as an autosomal, dominantly inherited trait, whereas in
the revisednosology, the familial occurrence is no longer required, a
prolapse of themitral valve and a systemic score<5 is sufﬁcient for
the diagnosisMVPS. Benign hypermobility syndrome (BHMS)was
deﬁned according to Simpson [2006]. An aneurysm of the thoracic
aorta of unknownorigin (UO)was deﬁned here as: dilatation of the
thoracic aorta (Z score 2) without evidence for a systemic or
familial disorder.
Statistical Analysis
Continuous data are reported asmean SD and categorical data as
percentages unless stated otherwise. Differences between groups
were tested using parametric or non-parametric tests, as appro-
priate. A P-value< 0.05 was considered to indicate statistical sig-




Between 1998 and 2008, 349 adult patients were referred to
our clinic for evaluation of possible MFS. Six patients were
excluded from analysis because of incomplete data, leaving a study
group of 343 patients. Men (n¼ 174) and women (n¼ 169) were
equally represented (P¼ 0.829) and the average age was 40
14 years. Reasons for referral are given in Figure 1, the most
common being aortic pathology (aortic dilatation or aortic
dissection). More than one reason for referral was present in
113 patients.
Patient Characteristics
In Table II and Figure 2, the characteristics of the patients
according to the 1996nosology are presented.Major cardiovascular
involvement (aortic root dilatation/type A aortic dissection)
was present in 28% of the patients. Ectopia lentis was present in
8% of patients and 40% of the patients had a family history of
MFS and/or an FBN1 mutation in the family. Dural ectasia was
evaluated in 88/343 patients and was detected in 31 of them (35%).
Major skeletal involvement was rare; it was present in only two
patients.
Diagnoses
InTable III, thediagnoses of all patients arepresented, both at initial
evaluationusing the 1996nosology andafter re-evaluation applying
the 2010 nosology. The patients were not clinically reevaluated, but
the 2010 nosology was applied to the already established character-
istics of the patients. In addition, diagnoses that were established
but not mentioned in the Ghent nosologies are also presented. At
initial evaluation, adiagnosis couldbemade in41%(n¼ 140)of the
patients. MFS was the most common diagnosis (13%), followed by
a thoracic aortic aneurysm of unknown origin (9%), FTAAD (6%)
and BHMS (6%). MVPS was found in 1%. Other diagnoses are
listed in Table III. No speciﬁc diagnosis could be made in 59%
(n¼ 203) of the patients. Thirteen of these patients without a
FIG. 1. Reasons for patients being referred to our Marfan outpatient
clinic (n¼ 343). MFS, Marfan syndrome.
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speciﬁc diagnosis had a high likelihood of MFS but did not (yet)
fulﬁll the 1996diagnostic criteria. They fulﬁlledoneof the following
proﬁles: (1) aortic root dilatation/type A aortic dissection com-
bined with ectopia lentis OR an FBN1 mutation, (2) (suspected)
family history of MFS AND an FBN1 mutation, and (3) ectopia
lentis AND an FBN1 mutation. Age did not differ signiﬁcantly
between patients with or without a diagnosis (38 14 years vs.
41 14 years; P¼ 0.123) and distribution of gender was equal
(P¼ 0.274).
After applying the 2010 Ghent nosology, a diagnosis could be
made in 48% (n¼ 165) of the patients (vs. 41% using the 1996
nosology, P< 0.001). There were several changes compared to the
diagnoses made at initial evaluation. The diagnosis of four patients
changed from no speciﬁc diagnosis to MFS. All four of these
patients belonged to the group of 13 patients with a high likelihood
of MFS at initial evaluation. Two of these patients had aortic root
dilatation and an FBN1 mutation. The other two patients had
aortic root dilatation and ectopia lentis. Conversely, in one
patient MFS could no longer be conﬁrmed using the 2010 criteria
(1/44 patients). This patient had a history of acute type A aortic
dissection, dural ectasia, dolichocephaly, malar hypoplasia, striae,
and no FBN1mutation. According to the 2010 nosology, this leads
to a systemic score of three, which together with the type A aortic
dissection was insufﬁcient for a ‘‘revised’’ diagnosis of MFS. In one
patient in whom initially no speciﬁc diagnosis could be made
because of ectopia lentis and an FBN1 mutation, the diagnosis
changed to ectopia lentis syndrome.
There were further major changes for MVPS: according to the
1996 nosology, MVPS was diagnosed in ﬁve patients (1%) but
according to the 2010 nosology MVPS was present in as many as
28 patients (8%). In three patients the diagnosis changed from
MASS phenotype to ‘‘no diagnosis.’’ Age did not differ signiﬁcantly
between patients with or without a diagnosis when using the 2010
nosology (38 14 years vs. 39 14 years; P¼ 0.205) and distribu-
tion of gender was equal (P¼ 0.476).
FBN1 Mutations
DNA analysis for FBN1 mutations was performed in 140 patients.
Of the 44 MFS patients diagnosed using the 1996 nosology,
34 patients had an FBN1mutation (77%). In 11 other patients, an
FBN1mutation was also present. They all had a high likelihood of
MFS but did not (yet) fulﬁll the diagnostic criteria (see previous
paragraph for the deﬁnition of these patients).
Of the 47 MFS patients diagnosed using the 2010 nosology,
36 patients had an FBN1mutation (77%). In nine other patients an
FBN1 mutation was also present. One had ELS and the other
eight all had a (suspected) family history of MFS and an FBN1
mutation.
Aortic Root Dilatation
In 65%(n¼ 52)of thepatientswith aortic root dilatation (n¼ 80) a
speciﬁc diagnosis could be established at initial evaluation, com-
pared to 70% (n¼ 56) after applying the 2010 nosology. Figure 3
summarizes the diagnoses of the patients with aortic root dilatation
using both the 1996 and 2010 Ghent nosologies.
TABLE II. Prevalence of Characteristics in 343 Patients Evaluated at Our Clinic According to the 1996 Ghent Nosology
System Major Minor None Not evaluated
Cardiovascular 95 (28%) 42 (12%) 192 (56%) 14a (4%)
Skeletal 2 (0.6%) 66 (19%) 246 (72%) 29b (8%)
Ocular 29 (8%) 7 (2%) 274 (80%) 33b (10%)
Familial/genetic 136 (40%) n.a. 207 (60%) —
Pulmonary n.a. 11 (3%) 296 (86%) 36b (10%)
Skin n.a. 114 (33%) 197 (57%) 32b (9%)
CNS 31 (10%) n.a. 57 (17%) 255b (74%)
n.a., not applicable; CNS, central nervous system.
aIn these 14 cases only DNA analysis was performed because of familial MFS with a pathogenic FBN1 mutation.
bIn these cases, evaluation was deemed not relevant, since regardless of the outcome this would not have had any clinical consequences.
FIG. 2. Prevalence of the characteristics according to the 1996
Ghent nosology of the 343 patients evaluated at our Marfan
outpatient clinic. CNS, central nervous system.
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DISCUSSION
Diagnostic Yield
Here, we have presented the diagnostic yield in our specializedMFS
clinic between 1998 and 2008. We used the 1996 Ghent nosology
and speciﬁc criteria for other disorders to evaluate the patients at
that time. The overall diagnostic yield at initial evaluation in
terms of establishing a speciﬁc diagnosis was 41%. Besides MFS
(13%) many other important diagnoses were made, including
FTAAD in 6%, LDS in 1% and familialMVPS in 1%of the patients.
Compared to a studybyRybczynski et al. [2008],whoalso evaluated
the diagnostic yield of patients referred for a possible diagnosis of
MFS, we diagnosed MFS less frequently (13%; n¼ 44 vs. their
50%; n¼ 138). This might be due to the low threshold for referral
to our center and a certain selection in the patients referred to
their institution. They evaluated 279 patients in 9 years from
the Hamburg metropolitan area (approximately 4.3 million
inhabitants), whereas we evaluated 343 patients in 10 years from
three northern provinces in the Netherlands (approximately 1.7
million inhabitants). However, Rybczynski et al. [2008] diagnosed
FTAAD in 3% and MVPS in 3% of their patients, which is
comparable to our results (6% and 1%, respectively) and argue
against a selection in the German study. Hamod et al. [2003]
reported on the diagnostic yield of 75patients referred for a possible
diagnosis of MFS and diagnosed MFS in 37% (n¼ 28) of
the patients. They did not report on other diagnoses that were
made [Hamod et al., 2003].
The cardiovascular relevance of a timely diagnosis of MFS is
obvious; MFS predisposes to aortic dissection and/or rupture
causing signiﬁcant morbidity and mortality. Lifelong follow-up
of the aortic (root) dimensions, beta-blocker therapy, prophylactic
aortic surgery (when thresholds are reached), and screening of
TABLE III. Diagnoses of the 343 Patients Evaluated at Our Clinic According to the 1996 and 2010 Ghent Nosologies
Diagnosis
Initial evaluation Re-evaluation
Othera 1996 nosology 2010 nosology Otherb
MFS 44 (13%) 47 (14%)
MVPS 5 (1%) 28 (8%)
MASS phenotype 6 (2%) 3 (1%)
EDS hypermobile type 5 (1%) 5 (1%)
BHMS 19 (6%) 19 (6%)
FTAAD 22 (6%) 22 (6%)
LDS 4 (1%) 4 (1%)
Ectopia lentis syndrome 1 (0.3%)
Thoracic aortic aneurysm UO 30 (9%) 31 (9%)
Remaining diagnosesc 5 (1%) 5 (1%)
No diagnoses 203 (59%) 178 (52%)
Total 343 (100%) 343 (100%)
BHMS, benign hypermobility syndrome; EDS, Ehlers–Danlos syndrome; FTAAD, familial thoracic aortic aneurysm and/or dissection; LDS, Loeys–Dietz syndrome; MFS, Marfan syndrome; MVPS,
mitral valve prolapse syndrome; UO, unknown origin.
aDiagnoses not mentioned in the 1996 Ghent nosology.
bDiagnoses not mentioned in the 2010 Ghent nosology.
cDuane syndrome, Lujan–Fryns syndrome, XYY-karyotype, dilated cardiomyopathy, congenital cataract.
FIG. 3. Diagnostic yield of aortic root dilatation using the 1996 and
2010 Ghent nosologies. MFS, Marfan syndrome; FTAAD, familial
thoracic aortic aneurysm and/or dissection; LDS, Loeys–Dietz
syndrome; MVPS, mitral valve prolapse syndrome; UO, unknown
origin. aThis patient had familial MVPS and aortic root dilatation
caused by a previously described FLNA mutation [Kyndt et al.,
2007].
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familymembers is indicated as soon asMFS is established [Aalberts
et al., 2008a; Loeys et al., 2010].
Likewise, timely diagnosis of FTAAD and LDS is important as
both are also characterized by aggressive aortic pathology [Aalberts
et al., 2008b]. Family members of patients with these syndromes
should alsobe screened. Finally, it is alsopreferably if familialMVPS
is recognized early since it can be accompanied by serious com-
plications, such as signiﬁcant mitral regurgitation, bacterial endo-
carditis, thromboembolism, and sudden cardiac death [Pocock
et al., 1984; Freed et al., 1999; Avierinos et al., 2002].
Aortic Root Dilatation
The diagnostic yield in patientswith aortic root dilatationwas 65% at
initial evaluation and 70% after applying the 2010 criteria. Diagnoses
that we made in this patient category were MFS, FTAAD, LDS,
familial MVPS, and Lujan–Fryns syndrome. In our opinion, all
patients younger than50yearswithunexplainedaortic rootdilatation
should be evaluated for a possible connective tissue disorder.
Implications of the Revised Ghent Nosology
In addition to establishing the diagnostic yield of our clinic, wewere
also able to evaluate the implications of the recent revision of the
MFS Ghent nosology. Although the 1996 nosology had a high
speciﬁcity for detecting patients with FBN1mutations [Loeys et al.,
2004] and was clinically useful, there were points of criticism,
especially in children, stimulating the development of the revised
nosology. In the 2010 nosology, emphasis is placed on cardiovas-
cular manifestations, ectopia lentis and genetic evaluation. Related
entities are deﬁned in the 2010 Ghent nosology as well. Using the
2010 nosology for our study, population led to several changes
compared to the outcome of the 1996 nosology. A diagnosis ofMFS
could be established in four additional cases. All patients had aortic
root dilatation combined with an FBN1 mutation (two cases) or
ectopia lentis (two cases). These cases nicely illustrate the hallmarks
and the clinical consequences of the 2010 nosology for MFS. The
diagnosis is more straightforward and speciﬁc characteristics of
MFSarehighlighted: aortic rootdilatation, ectopia lentis, andFBN1
mutations. On the other hand, skeletal features, CNS involvement
(dural ectasia), skin abnormalities, atypical cardiovascular, and
ocular manifestations are given less weight in the 2010 nosology.
This is illustrated by the patient who no longer fulﬁlled the
diagnostic criteria for MFS. Although this patient no longer has
MFS, this did not have any clinical consequences. Due to the type A
aortic dissection, regular imaging of the entire aorta was indicated
anyway, to timely discover and treat a possible post-dissection
aneurysm.
The use of the 2010 nosology led to a signiﬁcant increase in the
number of non-MFSdiagnosesmade. Thiswas due to an increase in
the number of patients diagnosed withMVPS. Familial occurrence
is no longer required in the 2010 nosology and therefore everyone
with solely a mitral valve prolapse qualiﬁes for MVPS. As mitral
valve prolapse is a commonvalvular disorder (estimatedprevalence
2–3%), mostly with a benign course (as opposed to certain familial
forms), it is debatablewhether it is useful to label all these patients as
mitral valve prolapse syndrome [Freed et al., 1999]. It does not have
clinical consequences as these patients are already well deﬁned and
guidelines for follow-up are available [Vahanian et al., 2007]. We
believe the term mitral valve prolapse is sufﬁcient in the large
majority of patients with this disorder.
At initial evaluation, a small number of patients (n¼ 13) with
no speciﬁc diagnosis had a high likelihood of MFS using the
1996 nosology. The 2010 nosology established deﬁnite MFS
in four of these patients and one of them could be diagnosed
as ectopia lentis syndrome. The remaining eight patients were
all patients with a (suspected) family history of MFS and
an FBN1 mutation. They should have regular echocardiographic
follow-up of aortic diameters anyway. An age limit of 50 years
for follow-up appears reasonable as the chances of developing
MFS are not very large if aortic diameters at that age are still
normal.
Finally, the revised criteria led to a less frequent diagnosis
of MASS phenotype. The criteria for this phenotype have
been changed slightly, but remain rather subjective. In particular,
the criterion of borderline aortic root dilatation is unsatisfying.
Strengths and Limitations
One strength of our study is that all the patients were seen by
the same team of specialists. Another is that we determined
the impact of the 2010 Ghent nosology by using it on patients
suspected ofMFSwhowere initially evaluated by the 1996 nosology,
rather than applying the new nosology to patients with established
MFS according to the old nosology, since this would introduce
a bias. In addition, we did not evaluate patients with a bicuspid
aortic valve at this particular clinic, since this could introduce a
bias in the outcome of the analysis. Our study is limited by the fact
that not all the Ghent criteria were evaluated in each patient.
CONCLUSION AND PRACTICAL IMPLICATIONS
The general diagnostic yield of our specialized clinic was high: at
initial evaluation, a diagnosis could be made in 41% of all referrals.
Besides establishing or excluding MFS, our clinic’s evaluation of a
patient can lead to the diagnosis of other clinically relevant con-
nective tissue disorders, like FTAAD, LDS, and familial MVPS.
Using the 2010 Ghent nosology led to a signiﬁcant increase in the
number of non-MFS diagnoses that were made, which was due to a
lowering of the diagnostic threshold ofMVPS. In addition, the 2010
nosology affords a more straightforward diagnosis of MFS in
patients with aortic root dilatation, ectopia lentis and FBN1muta-
tions. Finally, as the diagnostic yield in patients with aortic root
dilatation was particularly high, all such patients (age <50 years)
should be referred to a specialized MFS clinic to be evaluated for a
possible connective tissue disorder.
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